NUVB 241115 2.50C (NUVB241115C2500) Stock Options, News & Quotes

0.10
-0.25-71.43%

15min DelayClose Nov 15 16:00 ET

0.10High0.08Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Sep 15 19:34

WEEKEND NEWS

$Nuvation Bio (NUVB.US)$
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
Nuvation Bio (NYSE: NUVB) announced positive pooled data from TRUST-I and TRUST-II studies evaluating taletrectinib, a next-generation ROS1 TKI for advanced ROS1-positive NSCLC. Key findings include:
- 89% tumor shr...

Clintzilla

Sep 15 08:02

$Nuvation Bio (NUVB.US)$ big arse float but on watch

Trytosaveabit

Jun 26 16:16

Insider buy! Or should I say MORE buys! Hehehe

$Nuvation Bio (NUVB.US)$ Director Cui Xiangmin purchased 277.9K shares of common stock on Jun 25, 2024 at an average price of $2.97 for a total value of $825.35K.

Trytosaveabit

Jun 25 17:33

Insider buy

$Nuvation Bio (NUVB.US)$ Director Cui Xiangmin purchased 500K shares of common stock on Jun 20, 21, 24, 2024 at an average price of $2.98 for a total value of $1.49 million.

Trytosaveabit

Jun 3 04:00

Watching!

$Nuvation Bio (NUVB.US)$ Reported Saturday, Nuvation Bio Revealed Findings From The Crucial Phase 2 TRUST-I Trial Of Their Experimental ROS1 Inhibitor, Taletrectinib At The ASCO 2024
Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study
Responses were durable with long-term follow-up; 71% of TKI-naïve patients were still progression-free at two years
TRUST-I is one of t...